# Respiratory Failure

Acute respiratory failure requires parallel stabilization and etiologic diagnosis. Distinguish hypoxemic from hypercapnic physiology, identify airway or ventilatory-support failure early, select oxygen, high-flow, noninvasive, or invasive support by mechanism and trajectory, and reassess continuously for treatment failure.

**Clinical question:** How should physicians rapidly classify, stabilize, investigate, and support adults with acute hypoxemic, hypercapnic, or mixed respiratory failure?

Updated: 2026-08-20T23:22:21.933737Z

## What matters in practice
- Confirm gas-exchange failure with pulse oximetry plus arterial blood gas when hypoxemia, hypercapnia, acid-base status, or pulse-oximeter accuracy is clinically consequential; venous gases should not replace arterial assessment for acute hypoxemic respiratory failure.[22]
- Classify hypoxemia by physiology: a widened alveolar-arterial gradient suggests V/Q mismatch, shunt, or diffusion limitation; a normal gradient with hypercapnia supports alveolar hypoventilation.[22]
- Use noninvasive ventilation first line for acute hypercapnic COPD exacerbation when the patient is spontaneously breathing and can protect the airway; use CPAP or bilevel support for acute cardiogenic pulmonary edema.[21][22]
- For de novo acute hypoxemic respiratory failure, high-flow nasal cannula is generally preferred over face-mask NIV, but failure requires close surveillance and prompt intubation rather than prolonged ineffective support.[21][22]
- In ARDS, use low tidal volume ventilation based on predicted body weight, limit injurious pressures, use prone positioning for moderate-to-severe disease, and avoid routine high-frequency oscillatory ventilation.[20][21][23]

## Recognize failure and stabilize before completing the diagnosis

Airway, oxygenation, ventilation, and circulation are assessed and treated in parallel.

Acute respiratory failure is clinically important gas-exchange dysfunction from inadequate oxygenation, carbon dioxide elimination, or both. Practical thresholds include PaO2 below 60 mmHg or SaO2 below 88% for hypoxemic failure, and PaCO2 at least 45 mmHg with pH below 7.35 for acute hypercapnic failure.[22] Absolute blood-gas thresholds require interpretation against baseline, inspired oxygen concentration, altitude, chronic compensation, work of breathing, mental status, and hemodynamics.[1][11][22]

Immediately identify a threatened airway, inability to protect the airway or clear secretions, respiratory arrest or exhaustion, refractory hypoxemia, deteriorating consciousness, or shock. Clear upper-airway obstruction and provide supplemental oxygen and ventilatory support while diagnostic testing proceeds.[1][22] Mechanical ventilation is indicated for refractory hypoxemia, ventilatory failure, shock with metabolic acidosis, or airway compromise from altered mental status or obstruction.[21]
- Obtain continuous SpO2, respiratory rate, mental-status assessment, blood pressure, cardiac monitoring, and serial reassessment of work of breathing.[1][22]
- Obtain an ABG when defining oxygenation, PaCO2, pH, or acid-base compensation will change support or disposition. Peripheral venous pH may be informative, but venous PO2 and PCO2 have clinically important variation from arterial values, particularly in acute hypoxemic failure.[22]
- Use capnography as an adjunct for real-time ventilation monitoring and endotracheal tube confirmation; do not assume end-tidal CO2 accurately estimates PaCO2 when V/Q mismatch or low cardiac output is present.[1][22]

*Initial physiologic classification and immediate implications.[22]*

| Pattern | Key findings | Priority implication |
| --- | --- | --- |
| Hypoxemic failure | PaO2 <60 mmHg or SaO2 <88%.[22] | Determine whether hypoxemia reflects V/Q mismatch, shunt, diffusion limitation, hypoventilation, low inspired oxygen, or impaired oxygen delivery.[22] |
| Acute hypercapnic failure | PaCO2 ≥45 mmHg with pH <7.35.[22] | Identify reduced drive, pump failure, obstructive disease, increased dead space, or excess CO2 production; provide ventilatory assistance rather than oxygen alone.[22] |
| Acute-on-chronic hypercapnia | Elevated PaCO2 with increased bicarbonate plus acute acidemia or clinical deterioration.[11][22] | Compare with baseline; treat the precipitant and avoid assuming compensated chronic values are benign during acute decline.[11][22] |
| Mixed failure | Hypoxemia plus hypercapnia.[22] | Address both oxygenation and alveolar ventilation; select support according to airway protection, work of breathing, and anticipated trajectory.[22] |

## Use gas exchange and imaging to narrow the mechanism

Mechanism directs both the differential diagnosis and the likely response to oxygen or positive pressure.

For hypoxemia, calculate the alveolar-arterial oxygen gradient from an ABG when mechanism is uncertain. A widened gradient supports V/Q mismatch, shunt, or diffusion limitation; a normal gradient in a hypercapnic patient favors alveolar hypoventilation or low inspired oxygen tension.[22] V/Q mismatch usually improves with supplemental oxygen, whereas substantial shunt responds incompletely because perfused blood bypasses ventilated alveoli.[22]

Obtain portable chest radiography early to identify pneumothorax, focal or diffuse alveolar filling, pleural disease, and interstitial processes. Use CT selectively when radiography is nondiagnostic or when pulmonary embolism, occult infection, interstitial/inflammatory disease, or other cross-sectional pathology is suspected.[22] Bedside ultrasound may be added to the standard pathway when acute dyspnea remains diagnostically uncertain.[23]

For hypercapnia, distinguish reduced drive ('won't breathe') from ventilatory pump or airway limitation ('can't breathe') and excess dead space or CO2 production ('can't breathe enough'). Medication exposure, stroke, sleep-disordered breathing, obesity hypoventilation, hypothyroidism, neuromuscular disease, chest-wall disease, severe obstructive disease, and shock can each be causal or contributory.[22]
- Review medication and substance exposure promptly for opioids, benzodiazepines, barbiturates, alcohol, and other respiratory depressants; administer appropriate reversal when indicated.[22]
- In suspected neuromuscular or chest-wall failure, assess vital capacity, inspiratory muscle performance when feasible, secretion clearance, bulbar function, and aspiration risk. Hypercapnia may precede profound hypoxemia.[14][19]
- Interpret SpO2 cautiously in patients with darker skin pigmentation; occult hypoxemia despite SpO2 92% to 96% occurred more often in Black than White patients in a multicenter study, supporting ABG confirmation when clinical findings and oximetry diverge.[22]

*Mechanism-based clues in acute hypoxemia.[22]*

| Mechanism | Bedside or test clue | Expected response to oxygen |
| --- | --- | --- |
| V/Q mismatch | Widened A-a gradient; common with airway, parenchymal, or pulmonary vascular disease.[22] | Usually improves with supplemental oxygen.[22] |
| Shunt | Widened A-a gradient plus limited oxygen response; consider alveolar filling, collapse, or intracardiac/intrapulmonary shunt.[22] | May remain severe despite high FiO2.[22] |
| Alveolar hypoventilation | Hypercapnia with normal A-a gradient when no concomitant gas-exchange lesion exists.[22] | Oxygen improves hypoxemia but not hypercapnia.[22] |
| Diffusion limitation | Widened A-a gradient; may occur with interstitial disease or pulmonary vascular disease.[22] | Usually improves with supplemental oxygen.[22] |

## Match oxygen and noninvasive support to physiology and risk of failure

Support is a monitored therapeutic trial, not a substitute for reassessment or airway control.

Provide supplemental oxygen for hypoxemic respiratory failure while treating the cause. Across critically ill populations, an SpO2 range of approximately 90% to 98% appears safe, although oxygen targets remain uncertain and should avoid both severe hypoxemia and unnecessary hyperoxemia.[22] For patients with COPD or other risk of hypercapnic deterioration, target SpO2 88% to 92%.[21][22]

Use conventional nasal cannula or facemask for modest requirements and low work of breathing. When oxygen need exceeds the effective delivery capacity of conventional devices or work of breathing is increased, HFNC can deliver heated, humidified oxygen at flows up to 60 L/min with more reliable FiO2, low-level positive pressure, and upper-airway dead-space washout.[21][22]

NIV requires spontaneous breathing, airway protection, cooperation sufficient to remove the mask if vomiting occurs, and ability to manage secretions. Avoid NIV in cardiac or respiratory arrest, inability to protect the airway or clear secretions, facial trauma or surgery, and recent esophageal anastomosis.[21]
- Acute COPD exacerbation with respiratory acidosis: bilevel NIV is first-line when no contraindication exists and reduces intubation and mortality.[21][22]
- Acute cardiogenic pulmonary edema: CPAP or bilevel NIV improves respiratory distress and reduces intubation; evidence supports reduced mortality in meta-analysis.[21][22]
- De novo acute hypoxemic respiratory failure: HFNC is generally favored over face-mask NIV. If NIV is attempted, monitor closely because delayed intubation after NIV failure may worsen outcomes.[21][22]
- Reassess response using mental status, respiratory rate and effort, hemodynamics, SpO2/SaO2, and serial ABG pH and PaCO2. In acute hypercapnic COPD exacerbation, benefit from NIV should generally be evident within 1 to 4 hours.[22]

### When to abandon noninvasive support

Proceed to endotracheal intubation when noninvasive support fails to correct clinically significant hypoxemia or acidemia, PaCO2 and pH worsen, work of breathing remains unsustainable, airway protection is lost, or circulatory failure develops.[21][22] No universal time limit safely applies to HFNC in all hypoxemic syndromes; use trajectory-based reassessment rather than a fixed-duration trial.[22]
- Do not delay intubation for a patient with worsening encephalopathy, inability to clear secretions, escalating vasopressor requirement, refractory hypoxemia, or progressive fatigue.[1][21][22]

*Selection of noninvasive respiratory support in common adult presentations.[21][22]*

| Presentation | Preferred initial support | Key limitation |
| --- | --- | --- |
| Hypercapnic COPD exacerbation with acidosis | Bilevel NIV.[21][22] | Requires airway protection and close reassessment of pH, PaCO2, and clinical response.[22] |
| Acute cardiogenic pulmonary edema | CPAP or bilevel NIV.[21][22] | Treat the cardiogenic cause concurrently; intubate for instability or inadequate response.[22] |
| De novo acute hypoxemic respiratory failure | HFNC generally preferred over face-mask NIV.[21][22] | Persistent high work of breathing or inadequate oxygenation should trigger intubation planning.[22] |
| Postextubation high-risk patient | Preventive NIV or HFNC may reduce reintubation in selected patients after successful spontaneous breathing trial.[20][21] | Requires extubation readiness assessment, including consciousness, cough, secretions, and airway patency.[21] |

## Intubate deliberately and ventilate to minimize additional lung injury

Prepare for peri-intubation hypoxemia and hemodynamic collapse in patients with limited cardiopulmonary reserve.

Preoxygenate hypoxemic patients for at least 3 minutes with HFNC or NIV when feasible. Hypoxemia during rapid-sequence induction increases risk for arrhythmia, hemodynamic instability, and cardiac arrest; bag-mask ventilation during the apneic period reduces hypoxemia without increasing aspiration in a randomized trial.[22] Use vasopressors for hemodynamic instability during intubation and reserve fluid administration for suspected hypovolemia; a routine 500-mL crystalloid bolus did not reduce cardiovascular collapse.[22]

For invasive ventilation, select a mode and settings that deliver sufficient alveolar ventilation while limiting pressure- and volume-related injury. In ARDS, low tidal volume ventilation using 4 to 8 mL/kg predicted body weight is recommended; a 6 mL/kg predicted body weight target is the standard starting point in most protocols.[20][21] Monitor plateau pressure and driving pressure, especially when compliance is poor.[20][21]

For obstructive disease, actively assess for dynamic hyperinflation and auto-PEEP. Failure of expiratory flow to return to baseline before the next breath suggests incomplete exhalation; reduce respiratory rate or increase inspiratory flow to lengthen expiratory time. Severe auto-PEEP can impair venous return and cause hypotension.[21]
- A reasonable initial PEEP for many ventilated patients is 5 cm H2O; higher PEEP may be necessary in ARDS but must be balanced against overdistension and hemodynamic compromise.[21]
- Use the lowest FiO2 that maintains acceptable oxygenation; for most critically ill patients, SpO2 90% to 96% is reasonable, with 88% to 92% for patients at risk for hypercapnia.[21]
- Protocolized daily spontaneous breathing trials identify readiness for liberation. Pairing spontaneous breathing trials with daily sedation interruption reduces mechanical ventilation duration and improves long-term mortality.[20][21]

*Ventilator findings that should change bedside management.[21]*

| Finding | Likely interpretation | Action |
| --- | --- | --- |
| High peak pressure with relatively normal plateau pressure | Increased airway resistance from circuit obstruction, endotracheal tube obstruction, mucus, bronchospasm, asthma, or COPD.[21] | Check circuit and tube patency; treat obstruction or bronchospasm; assess for auto-PEEP.[21] |
| High plateau pressure | Reduced lung, pleural-space, or chest-wall compliance; consider ARDS, edema, pneumonia, atelectasis, pneumothorax, effusion, obesity, or abdominal distension.[21] | Assess cause, minimize injurious tidal volume and pressures, and evaluate PEEP response and hemodynamics.[21] |
| Expiratory flow persists at next inspiration | Dynamic air trapping/auto-PEEP.[21] | Lengthen expiration by lowering respiratory rate or increasing inspiratory flow; urgently decompress the circuit transiently if severe auto-PEEP causes shock.[21] |
| Worsening acidosis on low-tidal-volume ventilation | Insufficient minute ventilation or severe dead space; permissive hypercapnia may be necessary.[21] | Increase respiratory rate as tolerated; avoid auto-PEEP; ARDS protocols permit incremental tidal-volume increase if pH remains below 7.15 despite rate adjustment.[21] |

## Identify ARDS early and use evidence-based escalation

ARDS is a phenotype of acute hypoxemic respiratory failure requiring a distinct lung-protective strategy.

ARDS requires acute onset within 1 week, bilateral opacities not fully explained by effusions, collapse, or nodules, respiratory failure not fully explained by heart failure or fluid overload, and PaO2/FiO2 of 300 or less with PEEP or CPAP at least 5 cm H2O.[21] Severity is mild at PaO2/FiO2 201 to 300, moderate at 101 to 200, and severe at 100 or less.[21]

For moderate-to-severe ARDS, prone positioning for prolonged daily sessions is associated with improved mortality and is recommended by major guideline syntheses; evidence summaries describe use for more than 12 hours daily.[20][23] Higher PEEP may be considered in moderate-to-severe ARDS, but must be individualized to oxygenation, compliance, plateau pressure, hemodynamics, and evidence of overdistension.[20][21][23]

Avoid routine high-frequency oscillatory ventilation in moderate-to-severe ARDS.[20][23] Routine recruitment maneuvers are also not supported consistently across guideline syntheses, reflecting uncertain benefit and potential harm.[23] After initial resuscitation, conservative fluid management in ARDS or sepsis improves oxygenation and ventilator-free days, although not mortality.[21][23]
- Use low tidal volume ventilation, monitor plateau and driving pressures, and assess daily whether prone positioning and PEEP strategy remain indicated.[20][21][23]
- Consider VV-ECMO referral for severe refractory ARDS after optimized conventional management, including prone positioning when not contraindicated. ELSO criteria cited in guideline synthesis include PaO2/FiO2 below 80 mmHg or severe hypercapnic acidosis despite optimized ventilation.[23]
- Screen for treatable ARDS mimics or concomitant diagnoses, including hydrostatic pulmonary edema, diffuse alveolar hemorrhage, acute eosinophilic pneumonia, infection, acute interstitial disease, drug-induced injury, and malignancy when the course is atypical.[23]

*ARDS-specific escalation priorities.[20][21][23]*

| Clinical scenario | Action | Evidence context |
| --- | --- | --- |
| All ARDS | Low tidal volume ventilation using 4-8 mL/kg predicted body weight; monitor pressures.[20][21] | Guideline-supported lung-protective strategy.[20][23] |
| Moderate-to-severe ARDS | Use prolonged prone positioning when no contraindication exists.[20][23] | Guidelines and systematic review support mortality benefit with sessions exceeding 12 hours daily.[20] |
| Persistent hypoxemia despite lung-protective ventilation | Individualize PEEP; evaluate compliance, plateau pressure, hemodynamics, and overdistension.[21][23] | Higher PEEP is conditional in moderate-to-severe disease.[20][23] |
| Refractory severe ARDS | Refer early to an experienced ECMO center after optimized conventional management.[23] | VV-ECMO is conditionally recommended for severe ARDS in guideline synthesis.[23] |

## Monitor response, complications, and readiness to liberate

Support should be de-escalated as soon as the underlying process and respiratory mechanics permit.

Reassess oxygenation and ventilation after every meaningful change in oxygen delivery, NIV settings, ventilator settings, fluid strategy, bronchodilator treatment, or clinical status. For hypercapnic failure, serial pH and PaCO2 plus work of breathing are more actionable than pulse oximetry alone.[22] For ventilated patients, monitor airway pressures, waveforms, delivered tidal volume, respiratory rate, synchrony, gas exchange, sedation exposure, and hemodynamics.[20][21]

Daily liberation assessment should establish improving underlying disease, adequate gas exchange, hemodynamic stability, capacity to initiate inspiration, manageable secretions, cough strength, and airway protection. Daily spontaneous breathing trials are central; initial 30-minute trials with low pressure support had higher successful extubation rates than 2-hour T-piece trials in a randomized study.[21]

For patients at high risk for extubation failure, preventive NIV immediately after extubation can reduce reintubation; HFNC is another supported postextubation strategy.[20][21] Use a cuff-leak test in patients at high risk for postextubation stridor; if the patient otherwise meets extubation criteria but fails the test, systemic corticosteroid given at least 4 hours before extubation is recommended in guideline synthesis.[20]
- Pair spontaneous awakening and breathing trials when clinically appropriate.[20][21]
- Use targeted light sedation where feasible, assess delirium, and pursue early mobility protocols in stable patients; these measures are associated with fewer ventilator days or improved outcomes in evidence syntheses.[20]
- In progressive neuromuscular disease, discharge planning should include airway-clearance support, home ventilation assessment, and shared discussion of noninvasive versus invasive long-term support before crisis presentation when possible.[19]

*Liberation checkpoints after invasive ventilation.[20][21]*

| Checkpoint | What to assess | Action if unmet |
| --- | --- | --- |
| Physiologic readiness | Improving cause, adequate gas exchange, hemodynamic stability, spontaneous inspiratory effort.[21] | Continue support and correct reversible barriers before another trial.[21] |
| Spontaneous breathing trial | Clinical tolerance, respiratory distress, agitation, vital signs, and gas exchange.[21] | Return to supported ventilation and reassess contributors such as fluid overload, sedation, weakness, or unresolved disease.[21] |
| Extubation safety | Consciousness, cough, secretion burden, airway patency.[21] | Delay extubation or plan postextubation NIV/HFNC in selected high-risk patients.[20][21] |
| Postextubation surveillance | Work of breathing, oxygenation, ventilation, airway obstruction, secretion clearance.[20][21] | Escalate early if respiratory failure recurs; avoid delayed reintubation in progressive failure.[22] |

## Common questions

### What is the most useful initial distinction in adult respiratory failure?

Differentiate oxygenation failure from ventilatory failure using SpO2, ABG PaO2, PaCO2, pH, and clinical work of breathing. Then identify whether hypoxemia is due to V/Q mismatch, shunt, diffusion limitation, hypoventilation, low inspired oxygen, or impaired oxygen delivery.[22]

### When should HFNC be preferred over NIV?

For de novo acute hypoxemic respiratory failure, HFNC is generally preferred over face-mask NIV because evidence and ACP guidance favor HFNC. NIV remains preferred for acute hypercapnic COPD exacerbation and acute cardiogenic pulmonary edema when no contraindication exists.[21][22]

### When should NIV be considered a failure?

Escalate to intubation for worsening mental status, inability to protect the airway or clear secretions, persistent or worsening acidemia or hypercapnia, inadequate oxygenation, unsustainable work of breathing, or hemodynamic instability despite optimized NIV.[21][22]

### What ventilator strategy is required in ARDS?

Use low tidal volume ventilation based on predicted body weight, monitor plateau and driving pressures, consider higher PEEP in moderate-to-severe disease, and use prolonged prone positioning when appropriate. Routine high-frequency oscillatory ventilation should be avoided.[20][21][23]

### How should oxygen targets differ in COPD with hypercapnia risk?

Target SpO2 88% to 92% in COPD or other patients at risk for hypercapnic deterioration, while treating hypoventilation with ventilatory support rather than escalating oxygen alone.[21][22]

## References
1. Acute respiratory failure - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/853
2. Acute respiratory distress syndrome in adults — www.thelancet.com — https://www.thelancet.com/article/S0140-6736(22)01439-8/fulltext
3. Management of Critically Ill Adults With COVID-19 — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2763879
4. Acute respiratory failure in immunocompromised adults — www.thelancet.com — https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(18)30345-X/fulltext
5. Respiratory Failure and Ventilation — jamanetwork.com — https://jamanetwork.com/collections/42131/respiratory-failure-and-ventilation
6. Direct Oral Anticoagulant Use: A Practical Guide to ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.120.017559
7. Recommendations for Management of Clinically Significant ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0000000000000456
8. Guidelines for the Initial Assessment of Respiratory ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2110582025020199
9. Chronic Respiratory Failure - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/chronic-respiratory-failure
10. Respiratory Failure - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/respiratory-failure
11. Acute Respiratory Failure - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/acute-respiratory-failure
12. Development and Content Validation of a... : Critical Care Explorations — journals.lww.com — https://journals.lww.com/ccejournal/fulltext/2021/05000/development_and_content_validation_of_a.23.aspx
13. An Official American Thoracic Society Clinical Practice Guideline — academic.oup.com — https://academic.oup.com/ajrccm/article/209/1/24/8427573
14. NEUROMUSCULAR RESPIRATORY FAILURE — journals.lww.com — https://journals.lww.com/continuum/fulltext/2009/06000/neuromuscular_respiratory_failure.5.aspx
15. Drug Dosing Recommendations for All Patients: A Roadmap ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1923
16. FDA Approval Summary: Nalmefene Nasal Spray for the ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3514
17. 2024 CPDD Abstract Booklet - 2024 - Wiley Online Library — accp1.onlinelibrary.wiley.com — https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.1459
18. Regulatory utility of pharmacometrics in the development and ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12716
19. Guidelines - Noninvasive Positive Pressure Ventilation in the Home - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK554178
20. Evidence-Based Practices for Acute Respiratory Failure and Acute Respiratory Distress Syndrome — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7768938
21. Management of Respiratory Failure: Ventilator Management 101 and Noninvasive Ventilation — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8993478
22. Diagnosis and Management of Acute Respiratory Failure — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10910131
23. Guideline-based management of acute respiratory failure and ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9998250
24. Noninvasive Respiratory Support for Adult Patients with ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/42371750

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.